WallSt.net Announces Upcoming Interview With CEO Of Immunosyn Corporation

Thursday, November 15, 2007 General News
Email Print This Page Comment bookmark
Font : A-A+

LA JOLLA, Calif., Nov. 14 Stephen D. Ferrone,CEO of Immunosyn Corporation (OTC Bulletin Board: IMYN) will be featured in anexclusive interview with www.wallst.net scheduled for November 16 at 8:00 A.M.PST. The interview will be posted on www.wallst.net by 5 P.M. EST on November16, 2007.

The interview will cover topics including Immunosyn's market potential,growth initiatives, competitive edge, recent news and milestones thatinvestors should watch for.

"This interview is a part of our strategic market communication plan whichincludes meeting with brokers and institutional managers as well as takingpart in interviews," says Stephen D. Ferrone, CEO and President of Immunosyn.

To hear the interview in its entirety, visit http://wallst.net and clickon "Interviews." The interview can be accessed by locating the company'sticker symbol (IMYN) under the appropriate exchange (OTCBB) at the top of the"Interviews" section or by entering the company's ticker symbol (IMYN) in theSearch Archive window.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans tomarket and distribute life enhancing therapeutics. Currently, the company hasexclusive worldwide rights from its largest shareholder, ArgyllBiotechnologies, LLC, to market, sell and distribute SF-1019, a compound thatwas developed from extensive research into Biological Response Modifiers(BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatoryapproval of SF-1019 in several countries and preparations for clinical trialsare underway in both the US and Europe. Research suggests that SF-1019 hasthe potential to affect a number of clinical conditions includingcomplications from Diabetic Mellitus such as Diabetic Neuropathy (DN) anddiabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS)and neurological disorders such as Chronic Inflammatory DemyelinatingPolyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).

About WallSt.net:

www.wallst.net is owned and operated by WallStreet Direct, Inc., a whollyowned subsidiary of Financial Media Group, Inc. The Website is a leadingprovider of timely business news, executive interviews, multimedia content,and research tools. Financial Media Group, Inc. also ownshttp://www.mywallst.net, a financial social network for investors, FinancialFilings Corp., a provider of compliance solutions to publicly tradedcompanies, and WallStRadio, a business and finance podcast Website, FinancialFilings Corp. is expecting to receive two hundred eighty dollars from Sun CalEnergy, Inc. for the dissemination of this press release. For a complete listof our advertisers and advertising relationships, visithttp://wallst.net/disclaimer/disclaimer.asp.

The above news release contains forward-looking statements. Thesestatements are based on assumptions that management believes are reasonablebased on currently available information, and include statements regarding theintent, belief or current expectations of the Company and its management.Prospective investors are cautioned that any such forward-looking statementsare not guarantees of future performance, and are subject to a wide range ofbusiness risks, external factors and uncertainties. Actual results may differmaterially from those indicated by such forward-looking statements. Foradditional information, please consult the Company's most recent publicfilings and Annual Report on Form 10-K for its most recent fiscal year. TheCompany assumes no obligation to update the information contained in thispress release, whether as a result of new information, future events orotherwise.

SOURCE Immunosyn Corporation

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store